Firms Take Second Look At Risk Management Following High-Profile Recalls
This article was originally published in The Silver Sheet
Executive Summary
RISK MANAGEMENT ACTIVITIES ARE RECEIVING CLOSER SCRUTINY as FDA and device companies renew their focus on product safety in the wake of Guidant’s devastating series of recalls earlier this year. Risk analysis is required by the design control section of the Quality System Regulation and is "envisioned to be an inherent part of the decision process" throughout the rule, CDRH compliance director Tim Ulatowski reminds firms. FDA investigators may examine risk management practices while inspecting either design control or CAPA systems, experts note. Companies can ensure their activities are up to par by following the recommendations in ISO 14971, the international standard on the application of risk management to medical devices...
You may also be interested in...
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.
FDA Slaps High Risk Class I Label On Recall Of COVID-19 Diagnostics Made In Uncontrolled Plant
More than 160,000 of the tests were recalled, including 104,900 COVID Test Kits Nonsterile and 61,500 Clean Catch Urine Kits.